Bristol Myers Squibb Taps Evinova’s AI Platform to Rethink the Cost—and Speed—of Clinical Trials
Evinova announced today that Bristol Myers Squibb (BMS) has signed an agreement to deploy the Cost Optimizer module of Evinova’s Study Designer, part of its AI-native clinical development platform. The rollout will span BMS’s global clinical trial portfolio, signaling a broad commitment rather than a limited pilot.
